Lilly Expands Camurus Partnership, Secures Rights to FluidCrystal Tech for Amylin Receptor Agonists
LLY sits 73% above its 52-week low of $623.78 on light trading volume (0.3× avg).
Summary
Eli Lilly expanded its collaboration with Camurus, exercising an option to include amylin receptor agonists in their existing agreement. This grants Lilly exclusive rights to Camurus' FluidCrystal technology for developing long-acting cardiometabolic drugs in this new compound class. The expansion triggers an initial $5 million payment to Camurus, with potential for up to $870 million in future milestone payments and tiered mid-single-digit royalties. This strategic move broadens Lilly's pipeline in the cardiometabolic space, leveraging a technology designed for extended drug delivery.
At the time of this announcement, LLY was trading at $1,078.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,149.10. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.